Shares of Intercept Pharmaceuticals were up 45% shortly after the market open on Tuesday after the company on Monday announced development updates for several of its drug candidates.

The company, which has a market cap of more than $5 billion, also reported second quarter earnings, posting a larger than expected quarterly loss. 

Intercept is a biopharmaceutical company focused on the development of liver disease treatments.

Intercept shares, which were halted ahead of the company's announcement on Monday afternoon, were up nearly 250% year-to-date as of Monday's close, with the stock nearly quadrupling in one day on January 9 after the company stopped its FLINT trial of obeticholic acid for the treatment of nonalcoholic steatohepatitis, or NASH, due to "early efficacy."

In its 10-Q filed with the SEC on Monday afternoon, Intercept outlined new developments for its FLINT trial. 

On Monday, the company also gave the following updates on its development programs:

NASH Program FLINT trial data provided in 10-Q filing and to be discussed on today's conference call Phase 3 program initiation anticipated in 1H 2015, pending regulatory feedback Phase 2 lipid metabolism trial initiation anticipated in 1H 2015 PBC Program Fast Track designation granted by FDA Phase 3 confirmatory trial protocol finalization anticipated in 3Q 2014 and initiation planned around year-end 2014 Pre-NDA and pre-MAA meetings anticipated in 4Q 2014 with completed filings anticipated in 1H 2015 Primary Sclerosing Cholangitis (PSC) Program Double-blind phase 2 trial initiation anticipated year-end 2014 First clinical trial of OCA in this orphan indication with high unmet medical need INT-767 Phase 1 Trial Initiation Anticipated in 1H 2015's biotech reporter Adam Feuerstein broke down the results last night, writing that the rally in shares, "reflects a sense of relief that OCA head into a registration-worthy phase III study next year with less risk."  

See Also:

Check Out Taco Bell's New Upscale RestaurantThis Is What Modern-Day Sex Slavery In America Looks Like This Definitive Chart Destroys The Argument That We're Reliving The Bubble Of The Late 1990sEbola Drug Firm Shares Go Bonkers After FDA AnnouncementDRUG FIRM TEKMIRA SAYS FDA MAY ALLOW USE OF EBOLA DRUG ON PATIENTS